On April 15, 2020, Accelerate Diagnostics and BioCheck announced their commercial supply and collaboration agreement by which Accelerate will distribute the BioCheck MS-FAST system and BioCheck SARS-CoV-2 tests in North America, Europe and the Middle East.
The BioCheck MS-FAST system, a fully automated chemiluminescence immunoassay analyzer, and the BioCheck SARS-CoV-2 chemiluminescence-based tests are capable of processing blood, serum, or plasma samples in 30 minutes to detect IgG and IgM antibodies that confirm exposure and potential immunity to COVID-19. BioCheck has applied to receive FDA’s Emergency Use Authorization (EUA) for their SARS-CoV-2 tests.
The BioCheck SARS-COV-2 IgG/IgM test can help identify individuals who have been exposed to COVID-19 and may indicate protective immunity. The test can also help determine when it may be safe for recovered patients to resume normal activities.
Questions or requests for more information can be submitted using the form to the right.